EDMOCS trial pretends to evaluate if C-reactive protein (CRP) and procalcitonin (PCT) can predict intestinal anastomotic leaks before early discharge in advanced ovarian cancer surgery requiring intestinal resection. These markers have already been positively tested in colorectal cancer surgery, but not yet in ovarian surgery. Patients undergoing intestinal resection in ovarian cancer surgery will be included. C-reactive protein and PCT will be measured pre-operatively, and on the second, fourth and sixth postoperative day. Thirty-day readmissions, re-operations and mortality will be recorded.
Study Type
OBSERVATIONAL
Enrollment
92
C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
Hospital Universitari de la Vall d'Hebron
Barcelona, Spain
Number of patients with anastomotic leak detected by elevation of C-reactive protein and procalcitonin levels
To evaluate whether C-reactive protein (CRP) and procalcitonin (PCT) can predict anastomotic leak before early discharge.
Time frame: Within the first 30 days after the surgery
C-reactive protein and procalcitonin measures in patients without complications in ovarian surgery.
Defining normal range values of C-Reactive Protein and Procalcitonin during postoperative ovarian cancer surgery.
Time frame: Within the first six days after the surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.